Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics

Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics

Spectinamides 1599 and 1810 are lead spectinamide compounds currently under preclinical development to treat multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. These compounds have previously been tested at various combinations of dose level, dosing frequency, and route of...

Full description

Bibliographic Details
Main Authors: Keyur R. Parmar, Pradeep B. Lukka, Santosh Wagh, Zaid H. Temrikar, Jiuyu Liu, Richard E. Lee, Miriam Braunstein, Anthony J. Hickey, Gregory T. Robertson, Mercedes Gonzalez-Juarrero, Andrea Edginton, Bernd Meibohm
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Pharmaceutics
Subjects:
mPBPK
spectinamides
intratracheal PBPK
subcutaneous PBPK
interspecies extrapolation
granuloma model
Online Access:https://www.mdpi.com/1999-4923/15/6/1759

Internet

https://www.mdpi.com/1999-4923/15/6/1759

Similar Items